智通财经网·2025-12-05 08:12Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Pharmaceuticals Dongying (Jiangsu) Pharmaceutical Co., Ltd., received a drug registration certificate from the National Medical Products Administration for Minoxidil topical solution, allowing for production approval [1] Group 1: Product Details - Minoxidil topical solution was originally developed by Johnson & Johnson, with the 2% formulation launched in the U.S. in 1988 and the 5% formulation in 1997 [1] - The 2% formulation is indicated for the treatment of male pattern baldness and alopecia areata, while the 5% formulation is restricted to male use for the same conditions [1] Group 2: Regulatory and Financial Information - In January 2024, Shanghai Pharmaceuticals Dongying submitted a registration application for the product to the National Medical Products Administration, which was accepted [1] - As of the announcement date, the company has invested approximately RMB 6.56 million in research and development for this product [1]